The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | The safety and efficacy of isatuximab, bortezomib, lenalidomide, and dexamethasone in NDMM
In this video, Elias Mai, MD, University Hospital Heidelberg, Heidelberg, Germany, briefly discusses the safety and efficacy of isatuximab, bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed transplant-eligible multiple myeloma as observed in the GMMG HD7 trial (NCT03617731). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Consulting or Advisory Role, Honoraria, Research Funding, and Travel Accommodations and Expenses – Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi and Takeda.
